leukaemia

News

Roche and AbbVie’s Venclexta approved in CLL

Roche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for the treatment of people with previously untreated chronic lympho

News

Scotland says no to Yescarta, but backs Kymriah

Scotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types of lymphoma, but gave a green light to Novar

News

AbbVie, Roche eye first-line use of Venclexta in leukaemia

AbbVie and Roche’s Venclexta has hit the mark in a combination trial that could help it move into the treatment-naive chronic lymphocytic leukaemia (CLL) arena.

News

Cancer Research UK gives $4m funding to Glasgow Uni CML proj...

Cancer Research UK granted £3.1m (nearly $4m) to a group of researchers at the University of Glasgow to enable a pioneering study to help find new treatments for CML - chronic myeloid leuka

Market Access

FDA grants leukaemia drug ‘breakthrough’ status

A leukaemia drug has been granted ‘breakthrough therapy’ status by the US drug regulator.

News

Pfizer objects to NICE methods in leukaemia drug rejection

NICE has caused controversy by rejecting Pfizer’s Besponsa – a blood cancer drug that can give patients the chance to receive a potentially curative bone marrow transplant.

Roche and AbbVie’s Venclexta approved in CLL

Scotland says no to Yescarta, but backs Kymriah

AbbVie, Roche eye first-line use of Venclexta in leukaemia

Cancer Research UK gives $4m funding to Glasgow Uni CML proj...

FDA grants leukaemia drug ‘breakthrough’ status

Pfizer objects to NICE methods in leukaemia drug rejection

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

leukaemia

Editor's Picks